SC
OREX

Sculptor Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Sculptor Capital’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-27,200
Closed -$58K – 316
2017
Q3 		$58K Hold
27,200
– – ﹤0.01% 348
2017
Q2 		$79K Sell
27,200
-3,400
-11% -$10.2K ﹤0.01% 312
2017
Q1 		$105K Buy
+30,600
New +$121K ﹤0.01% 300

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Sculptor Capital's OREX Position: Q4 2017 in Review

Sculptor Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 27,200 shares — an estimated $58K sold.

Sculptor Capital first reported a position in OREX in Q1 2017 and held it in 3 quarters. The position peaked at $105K in Q1 2017. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

  • Sculptor Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Sculptor Capital sold 27,200 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $58K.
  • Sculptor Capital first reported a position in Orexigen Therapeutics, Inc. in Q1 2017 and held it in 3 quarters.
  • Sculptor Capital's Orexigen Therapeutics, Inc. position peaked at $105K in Q1 2017.
  • 41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Sculptor Capital's 13F filing for Q4 2017, filed 13 Feb 2018.